Peficitinib
- Generic Name
- Peficitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22N4O2
- CAS Number
- 944118-01-8
- Unique Ingredient Identifier
- HPH1166CKX
- Background
Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics, Drug Interactions, Colitis, Ulcerative, and RHEUMATOID ARTHRITIS, among others.
- Indication
用于治疗对常规疗法反应不足的类风湿性关节炎（包括预防结构性关节损伤）患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K
- First Posted Date
- 2012-07-11
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 843
- Registration Number
- NCT01638013
- Locations
- 🇯🇵
JP00131, Fukuoka, Japan
🇯🇵JP00164, Fukuoka, Japan
🇯🇵JP00176, Fukui, Japan
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2012-03-29
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT01565655
- Locations
- 🇲🇽
Cliditer S.A. de C.V., México, Distrito Federal, Mexico
🇵🇱Zespol Poradni Specjalistycznych, REUMED sp. Zo.o, Lublin, Poland
🇧🇬MHAT Burgas, Burgas, Bulgaria
A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
- Conditions
- Interventions
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 379
- Registration Number
- NCT01554696
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇧🇪Hospital Erasme, Brussels, Belgium
Single and Multiple Oral Administration Study of ASP015K in Healthy Nonelderly Volunteers
- Conditions
- Interventions
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 72
- Registration Number
- NCT01225224
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 124
- Registration Number
- NCT01096862
- Locations
- 🇺🇸
Renstar Medical Research, Ocala, Florida, United States
🇺🇸Derm Research, PLLC, Louisville, Kentucky, United States
🇺🇸Palmetto Clinical Trial Services, Greenville, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.